Back to discover
Drug

Artemisinin

In clinical development
Emerging researchLate-stage development

Also known as Quinghao, Quinghaosu, Artemisine, artemisinina.

RxNorm2367409ChEMBLCHEMBL269671ATCP01BE01UNII9RMU91N5K2
2
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Artemisinin ameliorates cognitive decline by inhibiting hippocampal neuronal ferroptosis via Nrf2 activation in T2DM mice.

Research2024-03-07Molecular medicine (Cambridge, Mass.)

A Double Blind, Randomized, Placebo Controlled, Multi Center Study of OT-101 in Hospitalized COVID-19 Subjects

Clinical trial2021-08-01Primary completion · ClinicalTrials.gov

A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19

Clinical trial2021-04-30Completed · ClinicalTrials.gov

Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.

Research2020-08-03Nature medicine

A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia

Clinical trial2011-05-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Artemisinin
Aliases & brands
QuinghaoQuinghaosuArtemisineartemisinina
RxNorm CUI
2367409
ChEMBL ID
CHEMBL269671
ATC codes
P01BE01
UNII
9RMU91N5K2

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2021
2
Late-stage (III+)
2
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 21Phase 31Phase 41

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202024
Major research themes5
Artemisinins1Cognitive Dysfunction1Diabetes Mellitus, Type 21Ferroptosis1Mutation, Missense1
Journals, researchers & institutions
Top journals
  • Molecular medicine (Cambridge, Mass.)1
  • Nature medicine1
Leading researchers
  • Ariey F1
  • Campagne P1
  • Criscuolo A1
  • Fidock DA1
  • Gu HF1
  • Guo M1
  • Legrand E1
  • Ma RD1
Leading institutions
free-text, unnormalised
  • Affiliated Hospital of Xiangnan University1
  • Columbia University Irving Medical Center1
  • Department of Physiology and Institute of Neuroscience1
  • Institut Cochin1
  • Institute of Anesthesiology1
  • Malaria Genetics and Resistance Unit-Institut Pasteur1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Arginine

Studied across 2 of the same disease areas as Artemisinin in the shared literature.

2 shared diseases1 shared paper
Histidine

Studied across 2 of the same disease areas as Artemisinin in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials